OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Cyberonics, Inc. announced on July 15, 2005, that the United States Food and Drug Administration (FDA) approved the Vagus Nerve Stimulation (VNS) Therapy System, the first FDA-approved implantable device-based treatment for depression. VNS has been approved "for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments." VNS Therapy is delivered from a small pacemaker-like generator . . .

OPEN MINDS, The Behavioral Health & Social Service Industry Analyst Industry News Cyberonics, Inc. announced on July 15, 2005, that the United States Food and Drug Administration (FDA) approved the Vagus Nerve Stimulation (VNS) Therapy System, the first FDA-approved implantable device-based treatment for depression. VNS has been approved "for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or older who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments." VNS Therapy is delivered from a small pacemaker-like generator . . .